Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001;18(7):551-60.
doi: 10.2165/00002512-200118070-00007.

Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine

Affiliations
Clinical Trial

Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine

P Abrams et al. Drugs Aging. 2001.

Abstract

Context: Tolterodine is a bladder-selective antimuscarinic agent designed for the treatment of overactive bladder. Traditional antimuscarinic therapies are poorly tolerated due to a high incidence of anticholinergic adverse events and consequently few patients remain on long term therapy.

Objective: To evaluate the long term efficacy and tolerability of tolterodine in patients with symptoms of overactive bladder.

Design: Twelve-month open-label extension of 4 randomised, placebo-controlled, double-blind, multinational, multicentre trials of 4 weeks' duration.

Patients: 714 patients (aged 18 to 92 years) with symptoms of overactive bladder who completed the double-blind portion of the studies.

Intervention: Tolterodine 2 mg twice daily for up to 12 months.

Main outcome measures: Micturition diary variables: number of micturitions per 24 hours, number of urge incontinence episodes per 24 hours, mean urine volume voided per micturition. Safety variables: adverse events, study discontinuation rate.

Results: A total of 441 patients (62%) completed 12 months' open-label treatment with tolterodine, which significantly reduced the number of micturitions per 24 hours [mean change -2.4, 95% confidence interval (CI) -2.7 to -2.2, median change -20%, p < 0.0001] and number of urge incontinence episodes per 24 hours (mean change -1.3, 95% CI -1.6 to -1.0, median change -74%, p < 0.0001), while the mean volume voided per micturition was significantly increased (+33 ml, 95% CI +28 to +38, median change +18%; p < 0.0001). 41% of patients reported dry mouth (27% mild, 10% moderate, 3% severe). Dosage reduction to 1 mg twice daily was required in 23% of patients. 15% of patients withdrew from the study due to adverse events, with 5% having associated dry mouth.

Conclusions: The high percentage of patients completing 12 months' treatment indicates that tolterodine is an effective and well tolerated agent for long term treatment of overactive bladder.

PubMed Disclaimer

References

    1. J Urol. 1991 Apr;145(4):813-6; discussion 816-7 - PubMed
    1. J Psychosom Res. 1986;30(6):691-8 - PubMed
    1. Urol Clin North Am. 1979 Feb;6(1):273-7 - PubMed
    1. Age Ageing. 1995 Jul;24(4):283-6 - PubMed
    1. Br J Urol. 1998 Jun;81(6):801-10 - PubMed

Publication types

LinkOut - more resources